Back to top
more

Pulmatrix (PULM)

(Delayed Data from NSDQ)

$2.02 USD

2.02
4,090

0.00 (0.00%)

Updated Apr 24, 2024 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Pulmatrix, Inc. (PULM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.76% and 24.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates

Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanghamitra Saha headshot

Bet on Rising P/E Investing With These Top 5 Stocks

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Pulmatrix, Inc. (PULM) Reports Q2 Loss, Tops Revenue Estimates

Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of 22.22% and 47.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Pulmatrix, Inc. (PULM) Q2 Earnings Expected to Decline

Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck Announces Detailed Data on Late-Stage Cough Candidate

Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.

Pulmatrix (PULM) Catches Eye: Stock Jumps 6%

Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sanghamitra Saha headshot

The Wining Sector & Its Top Stocks in Virus-Infected January

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

Pulmatrix Surges on License Agreement With Johnson & Johnson

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

Sanghamitra Saha headshot

Bet on 5 Top Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.